TH-CR-303

TH-CR-303 is an open-label Phase 2 trial designed to evaluate the safety and efficacy of glufosfamide in women with platinum-resistant ovarian cancer. This trial is closed to enrollment.

Disclosure of Risks

Please note that the safety and effectiveness of this product have not yet been established. As with other anti-cancer, this investigational product may not benefit you and may cause side effects. These side effects could be severe or even life threatening. There may be side effects that are not known or predictable at this time, but that may occur at the time of treatment or later. You should discuss these risks with your physician or a study doctor.